PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Mar 6, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new type of imaging scan called a PET/MR scan using a special substance called [68Ga]Ga-PentixaFor. The goal is to see if this advanced scan can help doctors get a more accurate picture of multiple myeloma, a type of cancer that mainly affects the bones. Currently, doctors use standard imaging tests like PET/CT scans and MRIs, which are good but may not capture all the details about the disease. By comparing the new scan with the standard methods, researchers hope to improve how multiple myeloma is diagnosed and monitored.

To be part of this study, participants need to be at least 18 years old and have a clinical diagnosis of multiple myeloma, specifically certain types that are outlined in the study criteria. Participants should not have had prior treatment beyond the first course, and they must be able to lie still during the scan for about 30 minutes. There are some reasons that might prevent someone from joining, like having certain health conditions or being pregnant. This study is not yet recruiting participants, but it aims to offer better diagnostic tools for those affected by this condition in the future.

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • Patient older than 18 years of age
• • Clinical diagnosis of (nonsecretory, oligosecretory, suspicion for extramedullary MM) MM. MM diagnosis is based on IMWG (International Myeloma Working Group) criteria.No treatment received beyond first course of
• • Exclusion criteria
• • Any contra-indications for MRI or 18F-FDG PET/CT imaging according to institutional guideline
• • Pregnancy (will be ruled out as per institutional protocol)
• • Inability to lie still in prone position in MRI for at least 30 min or PET/CT for at least 30 min
• • Patients or unwilling to use contraception during study and breastfeeding women can also not partake in this study
• • Inability to provide consent
• • Any hypersensitivity or known allergy to any component of the investigational product (\[68Ga\]Ga-PentixaFor)No concomitant other malignant hemato-oncological disease being diagnosed (i.e. additional lymphoma or leukemia)